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Background: The ideal aortic valve substitute for young adults (<65 years)
undergoing isolated aortic valve replacement (AVR) remains unknown. This
is partly due to the lack of data on long-term outcomes in this specific patient
population. The aim of this study was to determine long-term outcomes (sur-
vival and valve-related complications) in a contemporary series of consecutive
young adults undergoing isolated mechanical AVR.
Methods: Between 1997 and 2006, 1159 patients underwent AVR at our
institution. All patients undergoing concomittant or redo procedures were
excluded. Of those, 470 patients <65 years of age undergoing isolated
mechanical AVR were identified. Mean age of the patients was 53.2±9.2 years
(303 male and 167 female). Long term follow-up data were prospectively col-
lected through a dedicated valve clinic. Additional information was obtained
retrospectively from medical records. Lifetable analyses were used to deter-
mine age- and gender-matched general population survival in the province.
Mean follow up was 4.7± 4.7 years.
Results: Overall actuarial survival at 1, 5 and 10 years was respectively
98±2%, 93±2% and 80±3%, which is lower than the age- and gender-matched
general population in the province (Figure). Actuarial freedom from prosthetic
valve dysfunction was 99±1%, 92±2% and 88±8% at 1, 5 and 10 years respec-
tively. Actuarial freedom from valve reintervention was 98±1%, 93±1% and
89±2% at 1, 5 and 10 years respectively. Actuarial freedom from thrombo-
embolism was 96±1%, 90±2% and 87±2% at 1, 5 and 10 years respectively.
Conclusion: In young adults undergoing isolated mechanical AVR, sur-
vival is lower than expected in an age- and gender-matched general popula-
tion. Furthermore, there is a low but constant hazard of prosthetic valve
reintervention following mechanical AVR. Further studies are required to
determine the ideal valve substitute in young adults undergoing AVR.
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Purpose: Antithrombotic therapy after bioprosthetic aortic valve
replacement (AVR) is a debated issue. AVR is a frequent intervention
given the high prevalence of aortic stenosis and ageing population. The
absence of consensus highlights the need for an evaluation of actual clin-
ical practices.
Methods: Antithrombotic therapy was prospectively studied in 434
patients operated on for bioprosthetic AVR between January and April 2011
in 14 French centres. Patients previously treated with vitamin K antagonists
(VKA) were excluded. Mean age was 75±9 years, 58% were male and 33%
had coronary artery disease. Surgery was performed for aortic stenosis in 87%
of cases and was combined with coronary artery bypass grafting (CABG) in
23% of patients.
Results: After initial heparin therapy, in-hospital antithrombotic treatment
was : aspirin alone in 65% of cases; VKA alone in 9% of cases; VKA+ aspirin
in 19% of cases; and neither VKA nor aspirin in 7% of cases.
Factors that impacted the prescription of VKA were: coronary disease
(p<0.001), associated CABG (p<0.007) and post-operative supraventricular
arrhythmias (p<0.007). The strongest factor was the centre effect (p<0.0001)
(Figure 1). There was no relationship between the prescription of VKA and
the occurrence of in-hospital thromboembolic complications (p<0.21) or
bleeding (p<0.31).
Conclusion: This multicentre prospective study shows that VKA are pre-
scribed in only 28% of patients after bioprosthetic AVR, despite current rec-
ommendations in Europe. Although arrhythmias and coronary disease are
determinants of treatment, VKA prescription seems to be more closely related
to the centre effect than to patient characteristics. Homogenization of clinical
practices is therefore needed and randomized trials would be helpful in this
setting.
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Figure 1 – Centre effect
